Connor Iapoce

A new initiative from the HFSA highlights key findings on heart failure prevalence, risk, mortality and hospitalization rates in the United States.

Phase 1/2 trial data shows all patients with T1D treated with VX-880 achieved improved glycemic control and a reduction or elimination of external insulin needs.

Nondiabetic and diabetic patients without retinopathy experience similar results after treatment with an intravitreal dexamethasone implant for pseudophakic macular edema.

Switching to intravitreal dexamethasone improves visual outcomes, but does not significantly change subfoveal choroidal thickness or the choroidal vascularity index.

The technology could be an important step toward point-of-care diagnostics for microbial keratitis in primary care or other healthcare settings without a laboratory.

Overall quality of life appeared good during the COVID-19 pandemic, but the presence of retinal disease and the number of nonocular comorbidities were linked to negative impacts on vision-related quality of life.

Application of subretinal bevacizumab and tPA effectively removed subretinal hemorrhage secondary to nAMD, but anti-VEGF treatment must be continued.

Low allopurinol prescription rates and suboptimal dosing are of particular concern in adult patients in Asia with poorly controlled gout.

The use of SGLT2 inhibitors was associated with similar or lower risks of fractures as incretin-based drugs, even in the high-risk patient population.

Most patients were able to achieve clear or almost clear skin, and improvement of arthritis and difficult-to-treat areas, with guselkumab and risankizumab treatment.

An analysis of more than 1 million men found higher blood pressure in late adolescence was associated with an increased risk for major cardiovascular events in later life.

Granted a PDUFA date in March 2024, if approved, sotatercept would be a first-in-class medication to address the rare and progressive disease.

A systematic review of 11 randomized clinical trials found adults with gout exhibited similar hepatic safety profiles for both febuxostat and allopurinol treatment.

According to the approval, the percentage of study eyes returning to ≤0.2 mm from baseline pupil diameter was statistically significantly greater in the phentolamine ophthalmic solution group than placebo.

Type 1 diabetes was diagnosed later for men than women and for racial and ethnic minority adults than non-Hispanic White adults.

Announced by Ionis Pharmaceuticals, topline results show olezarsen met the study's primary endpoint with a statistically significant reduction in triglyceride levels versus placebo.

According to the analysis, high-performing primary care practices use similar strategies to manage change and quality improvement in care for people with diabetes.

Incidental CAC detection on ASCVD risk assessment revealed differences in prevalence by age, sex, and race and ethnicity.

The analysis reports clinical characteristics and the GA progression rate in an Asian population differ from those previously reported in White populations.

Phase 3 results show the non-inferior efficacy of biosimilar liraglutide to the originator in lowering HbA1C over 26 weeks of treatment.

Smartphone measurements were found to be accurate and precise compared with Hertel exophthalmometry or a high-resolution scanner.

The systematic review and meta-analysis of 13 studies found no evidence to support the use of topical NSAIDs for the treatment of central serous chorioretinopathy.

The analysis of questionnaire responses in Sweden suggests the socioeconomic factor of low household income had a crucial impact on vision-related quality of life.

Biosimilar infliximab-dyyb proves successful in achieving and maintaining the control of non-infectious uveitis in the study cohort.

Artificial intelligence use is growing across medicine. From imaging to chatbots, ophthalmology is the center of one of these transformations.

For DME eyes that did not sufficiently respond to prior treatment, the intravitreal implant was associated with improvements in both visual and anatomic outcomes.

Announced by Iveric Bio, topline results from the phase 3 GATHER2 clinical trial indicate monthly avacincaptad pegol significantly slowed GA growth compared to sham at 24 months.

Patients were treated with fewer anti-VEGF injections in 2020 compared to the previous year, but these changes did not significantly impact BCVA outcomes.

A post hoc analysis of the PREVENT trial suggests quarterly ranibizumab did not appear to affect drusen volume, drusen area, or GA progression compared to sham.

The association between antibiotic exposure and increased odds of AMD persisted after adjustment for well-established risk factors for the disease.